It has been demonstrated that targeting AXL with SLC-391, alone or in combination with chemotherapy or immune checkpoint blockade, results in tumour growth inhibition in multiple solid tumour and haematological tumour models [11,12,13,14,15,16,17], including lung cancer, colon cancer, CML, and AML. The gene discussed is AXL; the disease is acute myeloid leukemia.